drugset
Drugs / IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody
last change May 2026 re-read 3 minutes ago

IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody

Cell therapy

Developed for
malignant glioma
Investigated by
Emergency General Hospital, Department of Neurosurgery · Ming Yang · Pecking Union Medical College Hospital, Department of Neurosurgery · Peking University International Hospital

Trials 1

today NCT07481721 · Ph 1
20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07481721 May 2026 → Dec 2027 expected malignant glioma Ming Yang Not yet recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody ClinicalTrials.gov intervention name — accepted as the source's own label NCT07481721 ↗
Modality Cell therapy “Autologous IL13Rα2-targeted CAR-T cells” NCT07481721 ↗
Route Intravenous “peripheral intravenous infusion alone” NCT07481721 ↗